Order Article Reprints

Csikos C, Vágner A, Nagy G, Kálmán-Szabó I, Szabó JP, Ngo MT, Szoboszlai Z, Szikra D, Krasznai ZT, Trencsényi G, et al. In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [⁵²Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model. Diagnostics. 2023; 13(2):236. https://doi.org/10.3390/diagnostics13020236

Csikos, Csaba, Adrienn Vágner, Gábor Nagy, Ibolya Kálmán-Szabó, Judit P. Szabó, Minh Toan Ngo, Zoltán Szoboszlai, Dezső Szikra, Zoárd Tibor Krasznai, György Trencsényi, and et al. 2023. "In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [⁵²Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model" Diagnostics 13, no. 2: 236. https://doi.org/10.3390/diagnostics13020236

Csikos, C., Vágner, A., Nagy, G., Kálmán-Szabó, I., Szabó, J. P., Ngo, M. T., Szoboszlai, Z., Szikra, D., Krasznai, Z. T., Trencsényi, G., & Garai, I. (2023). In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [⁵²Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model. Diagnostics, 13(2), 236. https://doi.org/10.3390/diagnostics13020236